BIM-23190
Code | Size | Price |
---|
TAR-T39262-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits K i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly.
CAS:
182153-96-4
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.
I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.
T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.